Yes, the TNF receptor is considered a potential therapeutic target in cancer. Biologic agents that inhibit TNF, such as monoclonal antibodies and soluble receptors, are being explored in cancer treatment. However, their use is complicated due to the dual nature of TNF signaling. For instance, inhibiting TNF can reduce inflammation and potentially slow tumor progression, but it may also impair the immune system's ability to fight cancer cells.
